Superworth

Verrica Pharmaceuticals price to sales ratio VRCA

Market value divided by revenue over the last twelve months, since 2022.

Today, Nov 2, 2026
1.8×
5-year median
10.5×
Against its 5-year history
2nd
percentile: 0 is its lowest day, 100 its highest
5-year range
1.3× to 198×
Peer median
1.1×

Verrica Pharmaceuticals' price to sales ratio is 1.8× as of Nov 2, 2026.

That is below its 5-year median of 10.5×, lower than on 98% of days in the last 5 years.

Over that time it ranged from 1.3× in Nov 2025 to 198× in Jul 2022.

The median for 7 large drugmakers of a similar size is 1.1×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.8×1.6×3.9×
20252.5×1.3×10.5×
20243.4×3.4×88.2×
202396.1×16.5×96.1×
202212.6×10.8×198×

Against its peers

Companies in Drug Manufacturers - General nearest Verrica Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
VRCAVerrica Pharmaceuticals1.8×
SPROSpero Therapeutics1.3×
ATNMActinium Pharmaceuticalsn/m
LFVNLifevantage0.4×
NATRNatures Sunshine Products0.4×
CRMDCorMedix0.9×
ARVNArvinas1.6×
PBYIPuma Biotechnology2.3×
Peer median1.1×

Where Verrica Pharmaceuticals ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Verrica Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.